

# FerrÃ¡n CatalÃ¡-LÃ³pez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4231539/publications.pdf>

Version: 2024-02-01

179  
papers

127,690  
citations

8181

76  
h-index

3261

185  
g-index

217  
all docs

217  
docs citations

217  
times ranked

147028  
citing authors

#	ARTICLE	IF	CITATIONS
1	The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet Oncology</i> , The, 2022, 23, 27-52.	10.7	90
2	Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. <i>Lancet Public Health</i> , The, 2022, 7, e105-e125.	10.0	1,199
3	Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019. <i>JAMA Oncology</i> , 2022, 8, 420.	7.1	719
4	Mortality in Persons With Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder. <i>JAMA Pediatrics</i> , 2022, 176, e216401.	6.2	44
5	Design and methodological characteristics of studies using observational routinely collected health data for investigating the link between cancer and neurodegenerative diseases: protocol for a meta-research study. <i>BMJ Open</i> , 2022, 12, e058738.	1.9	1
6	How to properly use the PRISMA Statement. <i>Systematic Reviews</i> , 2021, 10, 117.	5.3	180
7	Use of multidimensional item response theory methods for dementia prevalence prediction: an example using the Health and Retirement Survey and the Aging, Demographics, and Memory Study. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 241.	3.0	2
8	Tracking development assistance for health and for COVID-19: a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990â€“2050. <i>Lancet</i> , The, 2021, 398, 1317-1343.	13.7	79
9	Global, regional, and national mortality among young people aged 10â€“24 years, 1950â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet</i> , The, 2021, 398, 1593-1618.	13.7	92
10	Reproducible research practices, openness and transparency in health economic evaluations: study protocol for a cross-sectional comparative analysis. <i>BMJ Open</i> , 2020, 10, e034463.	1.9	27
11	Global burden of 369 diseases and injuries in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet</i> , The, 2020, 396, 1204-1222.	13.7	7,664
12	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950â€“2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. <i>Lancet</i> , The, 2020, 396, 1160-1203.	13.7	890
13	Five insights from the Global Burden of Disease Study 2019. <i>Lancet</i> , The, 2020, 396, 1135-1159.	13.7	335
14	Citation impact was highly variable for reporting guidelines of health research: a citation analysis. <i>Journal of Clinical Epidemiology</i> , 2020, 127, 96-104.	5.0	22
15	Estimating global injuries morbidity and mortality: methods and data used in the Global Burden of Disease 2017 study. <i>Injury Prevention</i> , 2020, 26, i125-i153.	2.4	44
16	Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet</i> , The, 2020, 396, 1250-1284.	13.7	330
17	Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017. <i>Injury Prevention</i> , 2020, 26, i96-i114.	2.4	103
18	Global Burden of Cardiovascular Diseases and Risk Factors, 1990â€“2019. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2982-3021.	2.8	4,468

#	ARTICLE	IF	CITATIONS
19	Hyperosmolar therapy for acute brain injury: study protocol for an umbrella review of meta-analyses and an evidence mapping. <i>BMJ Open</i> , 2020, 10, e033913.	1.9	5
20	Reporting guidelines of health research studies are frequently used inappropriately. <i>Journal of Clinical Epidemiology</i> , 2020, 122, 87-94.	5.0	52
21	Digital health interventions for children with ADHD. <i>The Lancet Digital Health</i> , 2020, 2, e150-e151.	12.3	0
22	Global mapping of randomised trials related articles published in high-impact-factor medical journals: a cross-sectional analysis. <i>Trials</i> , 2020, 21, 34.	1.6	19
23	Global, regional, and national burden of chronic kidney disease, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2020, 395, 709-733.	13.7	2,858
24	Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3. <i>Lancet, The</i> , 2020, 396, 693-724.	13.7	87
25	Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017. <i>Injury Prevention</i> , 2020, 26, i12-i26.	2.4	44
26	The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017. <i>Lancet Oncology, The</i> , 2019, 20, 1211-1225.	10.7	199
27	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. <i>JAMA Oncology</i> , 2019, 5, 1749.	7.1	1,691
28	Association of Anorexia Nervosa With Risk of Cancer. <i>JAMA Network Open</i> , 2019, 2, e195313.	5.9	10
29	Prevalence and comorbidity of autism spectrum disorder in Spain: study protocol for a systematic review and meta-analysis of observational studies. <i>Systematic Reviews</i> , 2019, 8, 141.	5.3	10
30	Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995â€“2050. <i>Lancet, The</i> , 2019, 393, 2233-2260.	13.7	283
31	Transcriptomic metaanalyses of autistic brains reveals shared gene expression and biological pathway abnormalities with cancer. <i>Molecular Autism</i> , 2019, 10, 17.	4.9	30
32	Reporting guidelines for health research: protocol for a cross-sectional analysis of the EQUATOR Network Library. <i>BMJ Open</i> , 2019, 9, e022769.	1.9	10
33	Global, regional, and national burden of stroke, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2019, 18, 439-458.	10.2	2,005
34	Global, regional, and national burden of neurological disorders, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2019, 18, 459-480.	10.2	2,625
35	Global, regional, and national burden of brain and other CNS cancer, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2019, 18, 376-393.	10.2	359
36	Global, regional, and national burden of suicide mortality 1990 to 2016: systematic analysis for the Global Burden of Disease Study 2016. <i>BMJ: British Medical Journal</i> , 2019, 364, l94.	2.3	558

#	ARTICLE	IF	CITATIONS
37	Prevalence and comorbidity of attention deficit hyperactivity disorder in Spain: study protocol for extending a systematic review with updated meta-analysis of observational studies. <i>Systematic Reviews</i> , 2019, 8, 49.	5.3	8
38	Global, regional, and national burden of Alzheimer's disease and other dementias, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology</i> , The, 2019, 18, 88-106.	10.2	1,512
39	Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology</i> , The, 2019, 18, 56-87.	10.2	1,064
40	Spending on health and HIV/AIDS: domestic health spending and development assistance in 188 countries, 1995â€“2015. <i>Lancet</i> , The, 2018, 391, 1799-1829.	13.7	127
41	Trends in future health financing and coverage: future health spending and universal health coverage in 188 countries, 2016â€“40. <i>Lancet</i> , The, 2018, 391, 1783-1798.	13.7	172
42	The Burden of Cardiovascular Diseases Among US States, 1990-2016. <i>JAMA Cardiology</i> , 2018, 3, 375.	6.1	271
43	Flaws in the application and interpretation of statistical analyses in systematic reviews of therapeutic interventions were common: a cross-sectional analysis. <i>Journal of Clinical Epidemiology</i> , 2018, 95, 7-18.	5.0	48
44	The treatment of attention deficit hyperactivity disorder in children and adolescents: Epidemiology, multimorbidity and integrated health services. <i>Anales De Pediatr�� (English Edition)</i> , 2018, 88, 181-182.	0.2	0
45	Reproducible research practices are underused in systematic reviews of biomedical interventions. <i>Journal of Clinical Epidemiology</i> , 2018, 94, 8-18.	5.0	79
46	Global, regional, and national age-sex-specific mortality and life expectancy, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1684-1735.	13.7	716
47	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1736-1788.	13.7	4,989
48	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1923-1994.	13.7	3,269
49	Population and fertility by age and sex for 195 countries and territories, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1995-2051.	13.7	294
50	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1789-1858.	13.7	8,569
51	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1859-1922.	13.7	2,123
52	Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. <i>New England Journal of Medicine</i> , 2018, 379, 2429-2437.	27.0	959
53	Knowledge translation strategies to improve health care. <i>Medicina Cl��nica (English Edition)</i> , 2018, 151, 239-241.	0.2	0
54	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2018, 391, 2236-2271.	13.7	638

#	ARTICLE	IF	CITATIONS
55	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016. JAMA Oncology, 2018, 4, 1553.	7.1	1,260
56	Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2018, 392, 1015-1035.	13.7	2,005
57	Estrategias de transferencia del conocimiento para mejorar la atención sanitaria. Medicina Clínica, 2018, 151, 239-241.	0.6	2
58	Mapping of global scientific research in comorbidity and multimorbidity: A cross-sectional analysis. PLoS ONE, 2018, 13, e0189091.	2.5	24
59	Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA - Journal of the American Medical Association, 2017, 317, 165.	7.4	1,492
60	Future and potential spending on health 2015–40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. Lancet, The, 2017, 389, 2005-2030.	13.7	163
61	Evolution and patterns of global health financing 1995–2014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. Lancet, The, 2017, 389, 1981-2004.	13.7	204
62	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015. JAMA Oncology, 2017, 3, 524.	7.1	4,254
63	Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. Journal of the American College of Cardiology, 2017, 70, 1-25.	2.8	2,705
64	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 390, 231-266.	13.7	480
65	Rapid reviews for evidence synthesis. Medicina Clínica (English Edition), 2017, 148, 424-428.	0.2	2
66	Child and Adolescent Health From 1990 to 2015. JAMA Pediatrics, 2017, 171, 573.	6.2	306
67	Improving transparency of methods and results in cost-effectiveness analyses for cancer prevention, treatment and control. Medicina Clínica (English Edition), 2017, 148, 43-45.	0.2	0
68	Revisiones rápidas para la síntesis de la evidencia. Medicina Clínica, 2017, 148, 424-428.	0.6	3
69	Cancer and central nervous system disorders: protocol for an umbrella review of systematic reviews and updated meta-analyses of observational studies. Systematic Reviews, 2017, 6, 69.	5.3	24
70	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1084-1150.	13.7	573
71	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1260-1344.	13.7	1,589
72	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1151-1210.	13.7	3,565

#	ARTICLE	IF	CITATIONS
73	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2017, 390, 1211-1259.	13.7	5,578
74	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2017, 390, 1345-1422.	13.7	1,879
75	Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet Neurology</i> , The, 2017, 16, 877-897.	10.2	1,521
76	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2017, 390, 1423-1459.	13.7	284
77	Mejoría de la transparencia de métodos y resultados en los análisis coste-efectividad de intervenciones para prevenir, tratar y controlar el cáncer. <i>Medicina Clínica</i> , 2017, 148, 43-45.	0.6	0
78	The Burden of Mental Disorders in the Eastern Mediterranean Region, 1990-2013. <i>PLoS ONE</i> , 2017, 12, e0169575.	2.5	102
79	The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. <i>PLoS ONE</i> , 2017, 12, e0180355.	2.5	218
80	Anorexia nervosa and cancer: a protocol for a systematic review and meta-analysis of observational studies. <i>Systematic Reviews</i> , 2017, 6, 137.	5.3	6
81	Risk of mortality among children, adolescents, and adults with autism spectrum disorder or attention deficit hyperactivity disorder and their first-degree relatives: a protocol for a systematic review and meta-analysis of observational studies. <i>Systematic Reviews</i> , 2017, 6, 189.	5.3	11
82	Cost-effectiveness analyses in neuropsychiatry and mental health. <i>Actas Españolas De Psiquiatría</i> , 2017, 45, 127-36.	0.1	0
83	Cardiovascular and Renal Outcomes of Renin–Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses. <i>PLoS Medicine</i> , 2016, 13, e1001971.	8.4	75
84	The PRISMA statement extension for systematic reviews incorporating network meta-analysis: PRISMA-NMA. <i>Medicina Clínica (English Edition)</i> , 2016, 147, 262-266.	0.2	33
85	Declaración de transparencia: un paso hacia la presentación completa de artículos de investigación. <i>Revista De Psiquiatría Y Salud Mental</i> , 2016, 9, 63-64.	1.8	13
86	Improving transparency of scientific reporting to increase value and reduce waste in mental health research. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2016, 9, 1-3.	0.3	0
87	Improving transparency of scientific reporting to increase value and reduce waste in mental health research. <i>Revista De Psiquiatría Y Salud Mental</i> , 2016, 9, 1-3.	1.8	12
88	Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet</i> , The, 2016, 388, 1775-1812.	13.7	740
89	Quality of Methods and Results Reporting in Cost-effectiveness Analyses of Cardiovascular Interventions. <i>Revista Española De Cardiología (English Ed )</i> , 2016, 69, 876-877.	0.6	0
90	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet</i> , The, 2016, 388, 1603-1658.	13.7	1,612



#	ARTICLE	IF	CITATIONS
91	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	13.7	4,934
92	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1545-1602.	13.7	5,298
93	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1659-1724.	13.7	4,203
94	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1725-1774.	13.7	571
95	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1813-1850.	13.7	413
96	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. Lancet HIV, the, 2016, 3, e361-e387.	4.7	461
97	Declaration of transparency: A step towards complete reporting of research articles. Revista De Psiquiatría Y Salud Mental (English Edition), 2016, 9, 63-64.	0.3	0
98	The quality of reporting methods and results of cost-effectiveness analyses in Spain: a methodological systematic review. Systematic Reviews, 2016, 5, 6.	5.3	28
99	Global and National Burden of Diseases and Injuries Among Children and Adolescents Between 1990 and 2013. JAMA Pediatrics, 2016, 170, 267.	6.2	479
100	The global burden of injury: incidence, mortality, disability-adjusted life years and time trends from the Global Burden of Disease study 2013. Injury Prevention, 2016, 22, 3-18.	2.4	898
101	Epidemiology and Reporting Characteristics of Systematic Reviews of Biomedical Research: A Cross-Sectional Study. PLoS Medicine, 2016, 13, e1002028.	8.4	497
102	The Global Research Collaboration of Network Meta-Analysis: A Social Network Analysis. PLoS ONE, 2016, 11, e0163239.	2.5	33
103	Clinical equipoise and systematic reviews of randomized controlled trials. Medicina Clínica (English) Tj ETQq1 1 0.784314 rgBT / Overlock 10	0.2	0
104	Antihypertensive Medication: On the Right Path? Response. Revista Espanola De Cardiologia (English Ed) Tj ETQq0 0.0 rgBT / Overlock 10	0.0	0
105	Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials. Medicina Clínica (English Edition), 2015, 145, 511-519.	0.2	0
106	Uso de medicamentos antihipertensivos en España: tendencias nacionales en el periodo 2000-2012. Revista Espanola De Cardiologia, 2015, 68, 899-903.	1.2	8
107	The national burden of cerebrovascular diseases in Spain: A population-based study using disability-adjusted life years. Medicina Clínica (English Edition), 2015, 144, 353-359.	0.2	0
108	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 743-800.	13.7	4,951

#	ARTICLE	IF	CITATIONS
109	The Global Burden of Cancer 2013. <i>JAMA Oncology</i> , 2015, 1, 505.	7.1	2,269
110	Statins Use and Risk of Cataracts. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2015, 20, 344-345.	2.0	1
111	Prescripción de fármacos antihipertensivos: ¿en el buen camino? Respuesta. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 1191-1192.	1.2	0
112	Update on the Global Burden of Ischemic and Hemorrhagic Stroke in 1990-2013: The GBD 2013 Study. <i>Neuroepidemiology</i> , 2015, 45, 161-176.	2.3	1,002
113	Atlas of the Global Burden of Stroke (1990-2013): The GBD 2013 Study. <i>Neuroepidemiology</i> , 2015, 45, 230-236.	2.3	186
114	Sex Differences in Stroke Incidence, Prevalence, Mortality and Disability-Adjusted Life Years: Results from the Global Burden of Disease Study 2013. <i>Neuroepidemiology</i> , 2015, 45, 203-214.	2.3	159
115	Alzheimer's disease and cancer: the need of putting research into context with previous published systematic reviews. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 569-570.	2.5	4
116	Are licensed canine parvovirus (CPV2 and CPV2b) vaccines able to elicit protection against CPV2c subtype in puppies?: A systematic review of controlled clinical trials. <i>Veterinary Microbiology</i> , 2015, 180, 1-9.	1.9	28
117	Disability-adjusted Life Years Lost to Ischemic Heart Disease in Spain. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2015, 68, 968-975.	0.6	12
118	The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: protocol for a systematic review and network meta-analysis of randomized controlled trials. <i>Systematic Reviews</i> , 2015, 4, 19.	5.3	37
119	Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials. <i>Medicina Clínica</i> , 2015, 145, 511-519.	0.6	49
120	The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. <i>Annals of Internal Medicine</i> , 2015, 162, 777-784.	3.9	4,590
121	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. <i>Lancet, The</i> , 2015, 386, 2145-2191.	13.7	1,544
122	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 386, 2287-2323.	13.7	2,184
123	Use of Antihypertensive Drugs in Spain: National Trends From 2000 to 2012. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2015, 68, 899-903.	0.6	7
124	Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 385, 117-171.	13.7	5,847
125	The national burden of cerebrovascular diseases in Spain: A population-based study using disability-adjusted life years. <i>Medicina Clínica</i> , 2015, 144, 353-359.	0.6	11
126	The Quality of Reporting Methods and Results in Network Meta-Analyses: An Overview of Reviews and Suggestions for Improvement. <i>PLoS ONE</i> , 2014, 9, e92508.	2.5	82



#	ARTICLE	IF	CITATIONS
127	Alzheimer's Disease and Cancer: Current Epidemiological Evidence for a Mutual Protection. <i>Neuroepidemiology</i> , 2014, 42, 121-122.	2.3	23
128	Inverse and Direct Cancer Comorbidity in People with Central Nervous System Disorders: A Meta-Analysis of Cancer Incidence in 577,013 Participants of 50 Observational Studies. <i>Psychotherapy and Psychosomatics</i> , 2014, 83, 89-105.	8.8	164
129	La propiedad transitiva en los ensayos clínicos controlados: si B es mejor que A y C es mejor que B, ¿C será mejor que A?. <i>Revista Española De Cardiología</i> , 2014, 67, 597-602.	1.2	11
130	Global collaborative networks on meta-analyses of randomized trials published in high impact factor medical journals: a social network analysis. <i>BMC Medicine</i> , 2014, 12, 15.	5.5	30
131	Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2014, 384, 957-979.	13.7	609
132	Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2014, 384, 1005-1070.	13.7	786
133	Standard and intensive lipid-lowering therapy with statins for the primary prevention of vascular diseases: a population-based study. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 99-108.	1.9	13
134	Network meta-analysis for comparing treatment effects of multiple interventions: an introduction. <i>Rheumatology International</i> , 2014, 34, 1489-1496.	3.0	142
135	Global, regional, and national levels and causes of maternal mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2014, 384, 980-1004.	13.7	1,230
136	The Transitive Property Across Randomized Controlled Trials: If B Is Better Than A, and C Is Better Than B, Will C Be Better Than A?. <i>Revista Española De Cardiología (English Ed )</i> , 2014, 67, 597-602.	0.6	6
137	Progressive chronic kidney disease and dual inhibition of the renin–angiotensin–aldosterone system. <i>Preventive Medicine</i> , 2014, 60, 136.	3.4	0
138	Benefits and Risks of Intraoperative High Inspired Oxygen Therapy: Firm Conclusions Are Still Far Off. <i>Anesthesiology</i> , 2014, 120, 1051-1052.	2.5	6
139	Declaración de transparencia: promoviendo una publicación más completa, honesta y adecuada de los artículos científicos. <i>Revista Española De Salud Pública</i> , 2014, 88, 181-186.	0.3	2
140	Efficacy of osteoporosis therapies in a network meta-analysis with indirect comparisons: many concerns for new tools of evidence synthesis?. <i>Osteoporosis International</i> , 2013, 24, 1927-1928.	3.1	4
141	Safety of aprotinin in adult cardiac surgery: Revisiting the validity of a mixed-treatment comparison meta-analysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 145, 610.	0.8	1
142	Evaluation of Comparative Treatment Effects Using Indirect Comparisons. <i>Revista Española De Cardiología (English Ed )</i> , 2013, 66, 156-157.	0.6	4
143	Impacto de la asignación de la insuficiencia cardíaca como causa básica de defunción en el cálculo de la mortalidad prematura cardiovascular en España. <i>Revista Española De Cardiología</i> , 2013, 66, 1004-1005.	1.2	5
144	Global health priorities and research funding. <i>Lancet Infectious Diseases, The</i> , 2013, 13, 652.	9.1	0

#	ARTICLE	IF	CITATIONS
145	Coste-efectividad del tratamiento farmacológico del trastorno por déficit de atención e hiperactividad en niños y adolescentes: síntesis cualitativa de la evidencia científica. Revista De Psiquiatría Y Salud Mental, 2013, 6, 168-177.	1.8	11
146	Impact of Assigning Heart Failure as the Underlying Cause of Death on the Calculation of Premature Mortality Due to Cardiovascular Disease in Spain. Revista Espanola De Cardiología (English Ed ), 2013, 66, 1004-1005.	0.6	0
147	The increasing burden of mental and neurological disorders. European Neuropsychopharmacology, 2013, 23, 1337-1339.	0.7	69
148	Diabetes Mellitus and Risks of Dual Blockade of the Renin-angiotensin-aldosterone System. Revista Espanola De Cardiología (English Ed ), 2013, 66, 412-415.	0.6	2
149	Disease Burden Attributable to Major Risk Factors in Western European Countries: The Challenge of Controlling Cardiovascular Risk Factors. Revista Espanola De Cardiología (English Ed ), 2013, 66, 591-593.	0.6	1
150	Cost-effectiveness of pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: Qualitative synthesis of scientific evidence. Revista De Psiquiatría Y Salud Mental (English Edition), 2013, 6, 168-177.	0.3	4
151	La carga de enfermedad atribuible a los principales factores de riesgo en los países de Europa occidental: el reto de controlar los factores de riesgo cardiovascular. Revista Espanola De Cardiología, 2013, 66, 591-593.	1.2	4
152	Burden of disease in adolescents and young people in Spain. Revista De Psiquiatría Y Salud Mental (English Edition), 2013, 6, 80-85.	0.3	2
153	Burden of disease assessment with summary measures of population health for the Region of Valencia, Spain: a population-based study. Medicina Clínica, 2013, 140, 343-350.	0.6	12
154	Clinical evidence from randomized trials, network meta-analyses, and conflicts of interests. Journal of Thoracic and Cardiovascular Surgery, 2013, 146, 731-732.	0.8	0
155	Evaluación del efecto de los tratamientos utilizando comparaciones indirectas. Revista Espanola De Cardiología, 2013, 66, 156-157.	1.2	6
156	Carga de enfermedad en adolescentes y jóvenes en España. Revista De Psiquiatría Y Salud Mental, 2013, 6, 80-85.	1.8	25
157	Safety of multikinase inhibitors in metastatic renal cell carcinoma and indirect treatment comparisons. European Journal of Cancer, 2013, 49, 984-985.	2.8	0
158	Endothelin receptor antagonists-induced hepatotoxicity. Internal Medicine Journal, 2013, 43, 609-610.	0.8	1
159	Trends of uncontrolled blood pressure in Spain. Journal of Hypertension, 2013, 31, 630-631.	0.5	10
160	When Are Statins Cost-Effective in Cardiovascular Prevention? A Systematic Review of Sponsorship Bias and Conclusions in Economic Evaluations of Statins. PLoS ONE, 2013, 8, e69462.	2.5	25
161	Adherence to Evidence-Based Therapies After Acute Coronary Syndrome: A Retrospective Population-Based Cohort Study Linking Hospital, Outpatient, and Pharmacy Health Information Systems in Valencia, Spain. Journal of Managed Care Pharmacy, 2013, 19, 247-257.	2.2	46
162	Cost-effectiveness of iodinated contrast media for CT scanning in Spain: a decision-based analysis. Imaging in Medicine, 2012, 4, 193-199.	0.0	4

#	ARTICLE	IF	CITATIONS
163	Control of arterial hypertension in Spain. Journal of Hypertension, 2012, 30, 168-176.	0.5	43
164	Measuring the burden of disease and injury in Spain using disability-adjusted life years: An updated and policy-oriented overview. Public Health, 2012, 126, 1024-1031.	2.9	37
165	Olmesartan for the Prevention or Delay of Diabetic Nephropathy: Some Considerations. Revista Española De Cardiología (English Ed ), 2012, 65, 678-679.	0.6	0
166	Uso de olmesartán en la prevención o retraso de la nefropatía diabética: algunas consideraciones. Revista Española De Cardiología, 2012, 65, 678-679.	1.2	1
167	Evaluating New Health Technologies and Disease Burden in Developed Countries. Value in Health, 2012, 15, 987-988.	0.3	0
168	Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials. Medicina Clínica, 2012, 139, 421-429.	0.6	41
169	Renoprotective effects of renin-angiotensin-aldosterone system blockers in type 2 diabetes: demystifying multiple treatment comparisons in a network meta-analysis. Diabetologia, 2012, 55, 2547-2548.	6.3	4
170	Prevalence of attention deficit hyperactivity disorder among children and adolescents in Spain: a systematic review and meta-analysis of epidemiological studies. BMC Psychiatry, 2012, 12, 168.	2.6	115
171	Coauthorship and Institutional Collaborations on Cost-Effectiveness Analyses: A Systematic Network Analysis. PLoS ONE, 2012, 7, e38012.	2.5	25
172	Evaluación económica de intervenciones en enfermedades oncológicas en España: revisión sistemática y análisis comparativo. Farmacia Hospitalaria, 2012, 36, 141-147.	0.6	4
173	Revisión de las evaluaciones económicas de intervenciones en enfermedades cardiovasculares en España. Farmacia Hospitalaria, 2012, 36, 163-165.	0.6	0
174	New drug development. Lancet, The, 2011, 377, 902.	13.7	4
175	The burden of premature mortality in Spain using standard expected years of life lost: a population-based study. BMC Public Health, 2011, 11, 787.	2.9	36
176	Burden of disease and economic evaluation of healthcare interventions: are we investigating what really matters?. BMC Health Services Research, 2011, 11, 75.	2.2	27
177	Clinical Management of Abnormal Cytology Test Results and Costs Associated With the Prevention of Cervical Cancer in Spain. Journal of Lower Genital Tract Disease, 2010, 14, 311-318.	1.9	8
178	Does the development of new medicinal products in the European Union address global and regional health concerns?. Population Health Metrics, 2010, 8, 34.	2.7	23
179	Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain. European Journal of Public Health, 2008, 18, 674-680.	0.3	16